Gufic BioSciences Intrinsic Value
Gufic BioSciences intrinsic value. Gufic BioSciences (GUFICBIO) median intrinsic value is ₹417.77 from 10 valuation models (range ₹126–₹1049), vs current price ₹419.70 — -0.5% downside (Trading Near Calculated Value), margin of safety -0.5%. Compare with GUFICBIO stock valuation models to assess whether the stock is under or overvalued.
GUFICBIO Valuation Methods Summary — DCF, Graham Number & P/E
Gufic BioSciences intrinsic value across 10 models vs current price ₹419.70 — upside/downside and value range per method. For current market price and key ratios, visit Gufic BioSciences share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹191.84 | ₹153.47 - ₹230.21 | -54.3% | EPS: ₹8.72, Sector P/E: 22x |
| Book Value Method | asset | ₹1049.25 | ₹944.33 - ₹1154.18 | +150.0% | Book Value/Share: ₹665.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹839.40 | ₹755.46 - ₹923.34 | +100.0% | Revenue/Share: ₹1004.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹839.40 | ₹755.46 - ₹923.34 | +100.0% | EBITDA: ₹184.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹417.77 | ₹334.22 - ₹501.32 | -0.5% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹125.91 | ₹113.32 - ₹138.50 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹134.72 | ₹121.25 - ₹148.19 | -67.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹839.40 | ₹755.46 - ₹923.34 | +100.0% | ROE: 13.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹361.21 | ₹325.09 - ₹397.33 | -13.9% | EPS: ₹8.72, BVPS: ₹665.00 |
| Dividend Yield Method | dividend | ₹125.91 | ₹113.32 - ₹138.50 | -70.0% | DPS: ₹0.10, Target Yield: 2.5% |
GUFICBIO Intrinsic Value vs Market Price — All Valuation Models
Gufic BioSciences fair value range ₹126–₹1049 vs current market price ₹419.70 across 10 valuation models. Read GUFICBIO dividend track record for the complete payout history and dividend yield track record.
GUFICBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Gufic BioSciences median intrinsic value ₹417.77, current price ₹419.70 — Trading Near Calculated Value by 0.5%, margin of safety -0.5%.
What is the intrinsic value of GUFICBIO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Gufic BioSciences (GUFICBIO) is ₹417.77 (median value). With the current market price of ₹419.70, this represents a -0.5% variance from our estimated fair value.
The valuation range spans from ₹125.91 to ₹1049.25, indicating ₹125.91 - ₹1049.25.
Is GUFICBIO undervalued or overvalued?
Based on our multi-method analysis, Gufic BioSciences (GUFICBIO) appears to be trading near calculated value by approximately 0.5%.
GUFICBIO Financial Health — Key Ratios vs Industry Benchmarks
Gufic BioSciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.01 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.75x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GUFICBIO Cash Flow Quality — Operating & Free Cash Flow
Gufic BioSciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹45 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹123 Cr | ₹88 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹-8 Cr | ₹-59 Cr | Negative Cash Flow | 3/10 |